Astera Labs, Inc. Common Stock
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-98.2% vs price
Base Case (Median)
-94.7% vs price
Bull Case (75th pct.)
-88.5% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $2.21 | -99.2% | High (40%) |
| PE Comparable | $37.63 | -86.7% | Medium (25%) |
| Graham Number | $16.52 | -94.2% | Low (10%) |
| EV/EBITDA | $13.52 | -95.2% | Medium (20%) |
| EV/FCF | $41.20 | -85.4% | Medium (20%) |
| Earnings Power Value | $1.36 | -99.5% | Medium (50%) |
Based on 6 out of 8 methods, ALAB appears overvalued at the current price of $282.52. The base case fair value of $15.02 implies 94.7% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.